Naples Global Advisors LLC Raises Position in Johnson & Johnson (NYSE:JNJ)

Naples Global Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 46,070 shares of the company’s stock after buying an additional 539 shares during the quarter. Naples Global Advisors LLC’s holdings in Johnson & Johnson were worth $6,663,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Powers Advisory Group LLC lifted its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after buying an additional 61 shares in the last quarter. Knuff & Co LLC increased its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after acquiring an additional 64 shares during the period. Vertex Planning Partners LLC lifted its position in shares of Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after buying an additional 65 shares during the last quarter. Freedom Day Solutions LLC lifted its position in Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock valued at $1,016,000 after acquiring an additional 66 shares during the last quarter. Finally, Traphagen Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock worth $1,699,000 after purchasing an additional 67 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on JNJ shares. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Guggenheim upped their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $156.20 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a market cap of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average is $147.87 and its two-hundred day moving average is $156.00.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the business posted $2.29 EPS. The company’s revenue was up 5.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.